Literature DB >> 9674647

Insulin resistance in hypertension is associated with body fat rather than blood pressure.

I Toft1, K H Bønaa, T Jenssen.   

Abstract

The insulin resistance syndrome has been characterized by hypertension, upper body obesity, insulin resistance, hyperinsulinemia, glucose intolerance, and hypertriglyceridemia. Previous studies are inconsistent regarding the relationship between blood pressure and insulin resistance. We therefore compared the metabolic profile in 60 hypertensive subjects (mean+/-SD arterial pressure, 116+/-7 mm Hg) and 60 normotensive subjects (mean arterial pressure, 88+/-5 mm Hg) matched for age, gender, and body mass index. Hypertensives had significantly higher waist-to-hip ratio than normotensives (P=0.002). The groups did not differ in fasting plasma glucose (0.2 mmol/L, P=0.09), insulin (6 pmol/L, P=0.14), insulin sensitivity index (-0.01 micromol x kg(-1) x min(-1) x pmol/L(-1), P=0.7), and suppression of nonesterified fatty acids during a hyperglycemic clamp (1%, P=0.40). There were significant differences in fasting levels of C-peptide (50 pmol/L, P=0.004) and proinsulin (2 pmol/L, P=0.01), 2-hour postload levels of glucose (0.8 mmol/L, P=0.01) and insulin (84 pmol/L, P=0.01) after oral glucose challenge, and hepatic glucose production during the clamp (2.87 micromol x kg(-1) x min(-1), P=0.02). These differences were not significant when controlling for waist-to-hip ratio. Body mass index and waist-to-hip ratio were similarly associated with the insulin sensitivity index in the hypertensive (r=-0.59, P=0.0001 and r=-0.32, P=0.05) and normotensive (r=-0.58, P=0.0001 and r=-0.39, P=0.05) groups. Hypertension per se is not associated with insulin resistance. However, even small increments in both body mass index and waist-to-hip ratio, as often seen in hypertension, may lead to impairment in insulin sensitivity, probably mediated through altered lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674647     DOI: 10.1161/01.hyp.32.1.115

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  Mechanism of differential effects of antihypertensive agents on serum lipids.

Authors:  R D Brook
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

2.  Impact of Adiposity on Incident Hypertension Is Modified by Insulin Resistance in Adults: Longitudinal Observation From the Bogalusa Heart Study.

Authors:  Tao Zhang; Huijie Zhang; Shengxu Li; Ying Li; Yaozhong Liu; Camilo Fernandez; Emily Harville; Lydia Bazzano; Jiang He; Wei Chen
Journal:  Hypertension       Date:  2015-11-16       Impact factor: 10.190

3.  Insulin sensitivity and cardiovascular risk factors in hypertensive and normotensive native Ghanaians.

Authors:  A G B Amoah; D P Schuster; T Gaillard; K Osei
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

4.  Insulin acutely increases agonist-induced airway smooth muscle contraction in humans and rats.

Authors:  Becky J Proskocil; Gina N Calco; Zhenying Nie
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-01-27       Impact factor: 5.464

5.  Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men.

Authors:  Michaela Loebig; Johanna Klement; André Schmoller; Simone Betz; Nicole Heuck; Ulrich Schweiger; Achim Peters; Bernd Schultes; Kerstin M Oltmanns
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

6.  Impact of clinical characteristics of individual metabolic syndrome on the severity of insulin resistance in Chinese adults.

Authors:  Chang-Hsun Hsieh; Yi-Jen Hung; Du-An Wu; Shi-Wen Kuo; Chien-Hsing Lee; Wayne Huey-Herng Sheu; Jer-Chuan Li; Kuan-Hung Yeh; Cheng-Yu Chen; Dee Pei
Journal:  J Korean Med Sci       Date:  2007-02       Impact factor: 2.153

7.  The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells.

Authors:  Mansour Haddad
Journal:  Pathophysiology       Date:  2021-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.